Matches in SemOpenAlex for { <https://semopenalex.org/work/W36422939> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W36422939 endingPage "672" @default.
- W36422939 startingPage "666" @default.
- W36422939 abstract "Anthracyclines are integral components of most adjuvant chemotherapy regimens for surgically removed early breast cancer and are central to the accepted treatment standards. Recently the standard anthracycline regimen of doxorubicin plus cyclophosphamide was found to be inferior in preventing recurrence of breast cancer when compared to cyclophosphamide and docetaxel, questioning the necessity to expose patients to the potential cardiotoxicity of anthracycline in the adjuvant setting. Trastuzumab, a humanized monoclonal antibody against the extracellular domain of the human epidermal growth factor receptor 2 (HER2) has become the cornerstone of treatment of breast cancers that overexpress HER2 in the neo-adjuvant and metastatic setting. Unfortunately, the combination of anthracyclines and trastuzumab produces a high incidence of cardiotoxicity as seen in early trials of metastatic breast cancer. Five adjuvant trials combining trastuzumab with different anthracycline-based regimens have been reported, all of them revealing similar efficacy in reducing recurrence of breast cancer. The trastuzumab adjuvant trial 006 from the Breast Cancer International Research Group shows for the first time that a nonanthracycline-containing regimen with trastuzumab has equivalent efficacy in decreasing the recurrence of breast cancer, with less incidence of cardiotoxicity when compared to anthracycline-containing trastuzumab adjuvant regimens. Further trials are needed to determine the optimal length of adjuvant therapy with trastuzumab, as well as long-term side effects with special attention to cardiotoxicity." @default.
- W36422939 created "2016-06-24" @default.
- W36422939 creator A5063914778 @default.
- W36422939 creator A5078184758 @default.
- W36422939 date "2008-09-01" @default.
- W36422939 modified "2023-09-23" @default.
- W36422939 title "Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?" @default.
- W36422939 cites W1531775950 @default.
- W36422939 cites W168811426 @default.
- W36422939 cites W1848579801 @default.
- W36422939 cites W1876276942 @default.
- W36422939 cites W1964321121 @default.
- W36422939 cites W1964641698 @default.
- W36422939 cites W2007160568 @default.
- W36422939 cites W2045324973 @default.
- W36422939 cites W2094627540 @default.
- W36422939 cites W2095156669 @default.
- W36422939 cites W2098333537 @default.
- W36422939 cites W2115432999 @default.
- W36422939 cites W2115759102 @default.
- W36422939 cites W2126620646 @default.
- W36422939 cites W2132600317 @default.
- W36422939 cites W2135800076 @default.
- W36422939 cites W2137405271 @default.
- W36422939 cites W2141393790 @default.
- W36422939 cites W2144124503 @default.
- W36422939 cites W2146384083 @default.
- W36422939 cites W2214029008 @default.
- W36422939 cites W222594567 @default.
- W36422939 cites W2344444710 @default.
- W36422939 cites W2413468807 @default.
- W36422939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18827789" @default.
- W36422939 hasPublicationYear "2008" @default.
- W36422939 type Work @default.
- W36422939 sameAs 36422939 @default.
- W36422939 citedByCount "3" @default.
- W36422939 countsByYear W364229392017 @default.
- W36422939 countsByYear W364229392019 @default.
- W36422939 crossrefType "journal-article" @default.
- W36422939 hasAuthorship W36422939A5063914778 @default.
- W36422939 hasAuthorship W36422939A5078184758 @default.
- W36422939 hasConcept C121608353 @default.
- W36422939 hasConcept C126322002 @default.
- W36422939 hasConcept C143998085 @default.
- W36422939 hasConcept C2775930923 @default.
- W36422939 hasConcept C2776694085 @default.
- W36422939 hasConcept C2776755627 @default.
- W36422939 hasConcept C2776802502 @default.
- W36422939 hasConcept C2777863537 @default.
- W36422939 hasConcept C2777982462 @default.
- W36422939 hasConcept C2778233292 @default.
- W36422939 hasConcept C2779786085 @default.
- W36422939 hasConcept C2781190966 @default.
- W36422939 hasConcept C2781303535 @default.
- W36422939 hasConcept C2781413609 @default.
- W36422939 hasConcept C530470458 @default.
- W36422939 hasConcept C71924100 @default.
- W36422939 hasConceptScore W36422939C121608353 @default.
- W36422939 hasConceptScore W36422939C126322002 @default.
- W36422939 hasConceptScore W36422939C143998085 @default.
- W36422939 hasConceptScore W36422939C2775930923 @default.
- W36422939 hasConceptScore W36422939C2776694085 @default.
- W36422939 hasConceptScore W36422939C2776755627 @default.
- W36422939 hasConceptScore W36422939C2776802502 @default.
- W36422939 hasConceptScore W36422939C2777863537 @default.
- W36422939 hasConceptScore W36422939C2777982462 @default.
- W36422939 hasConceptScore W36422939C2778233292 @default.
- W36422939 hasConceptScore W36422939C2779786085 @default.
- W36422939 hasConceptScore W36422939C2781190966 @default.
- W36422939 hasConceptScore W36422939C2781303535 @default.
- W36422939 hasConceptScore W36422939C2781413609 @default.
- W36422939 hasConceptScore W36422939C530470458 @default.
- W36422939 hasConceptScore W36422939C71924100 @default.
- W36422939 hasIssue "9" @default.
- W36422939 hasLocation W364229391 @default.
- W36422939 hasLocation W364229392 @default.
- W36422939 hasOpenAccess W36422939 @default.
- W36422939 hasPrimaryLocation W364229391 @default.
- W36422939 hasRelatedWork W2029542561 @default.
- W36422939 hasRelatedWork W2110444464 @default.
- W36422939 hasRelatedWork W2144124503 @default.
- W36422939 hasVolume "6" @default.
- W36422939 isParatext "false" @default.
- W36422939 isRetracted "false" @default.
- W36422939 magId "36422939" @default.
- W36422939 workType "article" @default.